Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Bone marrow next generation sequencing minimal residual disease (NGS-MRD) positivity pre-allogeneic hematopoietic cell transplantation (HCT) predicts outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL): A planned analysis from the ptctc ONC1401 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

JDJ. Gregory DolanJTJulie‐An TalanoABAlice Bertaina

Discussion

Loading...

Member takes

Overview

Study reveals that pre-HCT NGS-MRD significantly predicts relapse and RFS in B-ALL patients, suggesting enhancements in monitoring strategies.

Key Points

  • To assess the predictive power of NGS-MRD for relapse and RFS in patients with B-ALL undergoing HCT.
  • Analyzed pre- and post-HCT samples using next generation sequencing and flow cytometry across 9 US centers.
  • Utilized multivariable Cox proportional hazards models to evaluate RFS and relapse rates.
  • Conducted statistical analysis to compare the predictive performance of NGS to traditional methods.
  • NGS showed higher sensitivity for MRD detection compared to flow cytometry, with 27.3% positive by NGS vs. 9.1% by flow.
  • NGS-MRD significantly predicted relapse risk, outperforming MFC in both BM and PB assessments.
  • Lower relapse rates were observed for patients without detectable MRD pre-HCT, indicating NGS's potential for better monitoring.

Cite This Study

Dolan et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e18dhttps://doi.org/10.1182/blood-2025-511
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701)2025 · 2 citations
  2. 2Longitudinal clonotype tracking by next-generation sequencing (NGS) based T-cell receptor (TCR) rearrangement measurable residual disease (MRD) assay in frontline adult T-acute lymphoblastic leukemia (ALL)2025
  3. 3Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring2025
  4. 4Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL2025 · 9 citations
  5. 5Post-transplant monitoring of multiparameter flow-cytometry (MFC)-based measurable residual disease (MRD) assessment combined with T-cell chimerism following allogeneic stem cell transplantation (HCT) in Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)2025